Evidence map›Paper›PMID 19371772›Full record

ReviewBiochimica et biophysica acta2009

PGC-1alpha in aging and anti-aging interventions.

Rozalyn Anderson, Tomas Prolla

Abstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. CoQNutrients · 2022
    Review
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rozalyn AndersonWisconsin National Primate Research Center, Madison, WI 53715, USA. rmanderson5@wisc.edu
Tomas Prolla

Funding

INSTITUTIONAL CTSA (UW-MADISON): CLINICAL TRIALSUL1RR025011 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2007 to 2011
$29.5M
THE MITOCHONDRION--DNA INTEGRITY AND ENZYME ACTIVITIESP01AG011915 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI COLMAN, RICKI J · 1994 to 2010
$13.1M
PLANNING AND EVALUATIONP20CA103697 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI WEINDRUCH, RICHARD · 2003 to 2007
$3.0M
NCI NIH HHS P20 CA103697NCRR NIH HHS UL1 RR025011NCRR NIH HHS UL1RR025011NIA NIH HHS AG11915NIA NIH HHS P01 AG011915
6 · The paper itself

Abstract

Deregulation of mitochondrial function is a common feature in multiple aspects of aging. In addition to playing a role in aging-associated disease, decline in mitochondrial energy metabolism is likely to be important in the development of metabolic disease. Furthermore, altered mitochondrial function is a conserved feature in caloric restriction--a dietary intervention that delays aging in diverse species. The transcriptional co-activator PGC-1alpha is a critical regulator of mitochondrial energy metabolism and biogenesis. PGC-1alpha is uniquely poised as a potential target for correcting the effects of age on mitochondrial decline. We describe the cellular and tissue specific mechanisms of PGC-1alpha regulation and illustrate how these pathways may be involved in the aging process.

Indexed as

AgingAnimalsAntioxidantsHeat-Shock ProteinsHumansMitochondriaModels, BiologicalPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaProtein Processing, Post-TranslationalResveratrolStilbenesTranscription FactorsAntioxidantsHeat-Shock ProteinsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPARGC1A protein, humanResveratrolStilbenesTranscription Factors

Identifiers

PMID19371772
PMCPMC2743759

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.